Abstract
Several candidates for a vaccine against Burkholderia pseudomallei, the causal bacterium of melioidosis, have been developed, and a rational approach is now needed to select and advance candidates for testing in relevant nonhuman primate models and in human clinical trials. Development of such a vaccine was the topic of a meeting in the United Kingdom in March 2014 attended by international candidate vaccine developers, researchers, and government health officials. The focus of the meeting was advancement of vaccines for prevention of natural infection, rather than for protection from the organism’s known potential for use as a biological weapon. A direct comparison of candidate vaccines in well-characterized mouse models was proposed. Knowledge gaps requiring further research were identified. Recommendations were made to accelerate the development of an effective vaccine against melioidosis.
Highlights
Several candidates for a vaccine against Burkholderia pseudomallei, the causal bacterium of melioidosis, have been developed, and a rational approach is needed to select and advance candidates for testing in relevant nonhuman primate models and in human clinical trials
The potential for humans to be infected with B. pseudomallei by inhalation, the low infective dose by this route, and difficulties associated with diagnosis and treatment have led to this organism being considered to be at high risk for deliberate misuse as a weapon [3,4,5]
A notable lack of standardization of protocols has resulted in variability in the animal models used; route of inoculation; challenge strains (K96243, 1026b, 576, NCTC13392, NCTC4845, and NCTC13179); route of B. pseudomallei challenge; challenge dose; and duration of the followup period for assessing mortality rates among acute and chronic challenge models (5 days to 5 months) [8,9,10]
Summary
Several candidates for a vaccine against Burkholderia pseudomallei, the causal bacterium of melioidosis, have been developed, and a rational approach is needed to select and advance candidates for testing in relevant nonhuman primate models and in human clinical trials Development of such a vaccine was the topic of a meeting in the United Kingdom in March 2014 attended by international candidate vaccine developers, researchers, and government health officials. The bacterium Burkholderia pseudomallei, the causal organism of melioidosis, was designated as a category B select agent by the US Centers for Disease Control and Prevention (CDC) and as a Tier 1 select agent by National Select Agent Registry (NASR), a joint program of the CDC and the Animal and Plant Health Inspection Service of the US Department of Agriculture These designations have led to considerable research funding to develop a melioidosis vaccine [1,2]. Comparison of potential usage and animal models required for development of vaccines against naturally acquired melioidosis versus melioidosis vaccines for biodefense purposes*
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
